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Violence in th e psychiatric setting may be perpet rated by patients with a
var ie ty of diagnoses including characte r d isorders, episodic dyscontrol syn-
dromes, and drug or a lco hol intoxication . The vio lent behavio r of ag gressive
psychotic patients is typicall y the most bi zarre , unpred ictable , and th e least
responsive to intervention with neuroleptics or lithium carbonate. Carbamaze-
pine , an estab lished anticonvulsant , has ac h ieved growing prominence as an
adj unc t ive measure in treatment of th e vio lent psych o tic . This paper will review
th e literature and summar ize th e posited p ha r maco logica l mech anisms,
reported sid e effects, and clinical experience wit h carbamazepine in controll ing
th e symptoms of vio lence and aggression in psychosis .
An ticonvul san ts were first used in the treatment of aggressive psych o tic
patients in 1943 (1). Carbamazepine , introduced in 1963 as an anticonvulsant
particularly effec tive in temporal lobe epilepsy, has been reported to be useful in
treating aggressio n associated wit h psych osis in patients with bipolar affective
di sorder, schizoaffec tive di sorder , and sch izophrenia with and without EEG
ab no r malit ies . T he first successfu l open clin ical tria ls in patients with bipolar
d isorde r were co nd ucted in Japan in the early 197 0 's. Two groups o f in vestiga-
tors demonstrat ed anti-man ic and sligh t anti-depressive effects in 75% (2) and
55%, respectively, of th eir patients with bipolar affective disorder, and prophy-
lactic effects in both manic (7 1%) and depressive (64 %) episodes (3 ,4), although
some patients recei ved combinat ions of carbamazepine and lith ium and/or
other drugs.
A ser ies of double-blind controlled trials foll owed these stu d ies . Okuma et
a l. compared chlorpromazin e and car ba mazepine and reported equivalent
anti-manic effects (5) . Ballenger and Post cond uc ted double-bl ind , placebo-
controlled trials of carbamazepine in nine manic patients, seven of whom had
partial to marked therapeutic responses (6); a n additio nal pati ent who had been
unresponsive to lithium and other anticonvulsants a lso improved on carbamaze-
pine (7). Subsequent published case s and open stud ies reported the efficacy of
ca rbamazepine combined with lithium carbonate (8- 15), par ticul arl y in pati ents
in whom lithium was less effect ive or who exper ie nced a contin uo us circular or a
rapidly cycling course . Post et al. also provid ed case reports wh ich suggest th at
car bamazep ine ma y have prophylacti c e ffec ts (16). Okuma et a l. conducted a
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double-blind controlled trial showing prophylacti c effec ts of ca rbamazepine in
60 % and placebo in 22.2% of their patients (V-test, p < 0.10) (17). Kishimoto et
at. found some prophylactic effect s of carbamazepine in manic and depressive
episodes in 75 % of their thirty-two cases, all foll owed for at least seven years; the
effects being significantly greater in the group with onset of illness before age 20
(p < 0.0 I, Fisher's exact test) (18) . A double-blind controlled study comparing
carbamazepine plus haloperidol and placebo plus haloperidol in lit h ium carbon-
ate- and neuroleptic-resistant patients with "excite d psych oses" found a signifi-
cant improvement of sympto ms including " host ility" and "excitement" in the
treatment group over th e placebo group (p < .03), although both groups
improved (19).
There are also reports of pati ents with sch izoaffective disorder who
responded to ca rbamazep ine . Folks, King et at. obse rved improvement in two of
three such patients given carbamazepine (14) . Brooks and Lessi n re ported the
successful carbamazepine treatment of a man with sch izoa ffec tive disorder and
resi stant lithium-induced nephrogenic diabet es ins ip idus (20). Kraft, Hass en-
feld , and Zarr published th e case of a previously treatmen t-refracto ry patient
whose auditory hallucinations responded to carbamazepine (21) . Despite
encouraging case reports, to date th ere has been no co ntrolled trial of carbarna-
zep ine in sch izoaffec tive disorder.
Carbamazepine ha s been prescribed for schizophrenics wit h and without
abnormal EEG's in whom violent behavior was particularl y problematic. In an
open trial, Hakola and Laulumaa treated e igh t schizophren ics with combina-
tions of carbamazepine and neuroleptics. The eigh t pati ents all showed EEG
abnormalities but had not been diagnosed as epilep tic. Foll owin g the combina-
tion treatment, all eight patients showed decrea sed aggressive behavior , and
four of th e eight showed diminished symptoms of schizophrenia as well (22).
Luchins had similar results in six schizophren ics with norm al EEG's (23) , and
Yassa and Dupont reported a similarly-responsive case (24). Ne ppe conducted a
double-blind, randomized study of carbamazepine in e leven chronic schi zo-
phrenics with EEG abnormalities, e ight of whom improved while on carbamaze-
pine (p = .03 , Wilcoxon; p < .005, ANOVA) (25). In contrast, Stevens and
Bigelow et at. reported two cases of psychosis aggravated by th erapeut ic doses of
carbamazepine (26). In summary, th e available literature suggests th at carbama-
zepine may be a useful adjunctive measure in the treatment of agg ressive or
violent psychotic patients, some of whom may ha ve EEG abnormalities. Carba-
mazepine 's apparent effect on both aggressive behavior and psych otic sym ptoms
raises qu estions about the compound's mechanism of ac tion . T he only anticon-
vulsant with a tricyclic structure , carbamazepine is a polycyclic d rug whose steric
structure resembles th at of chlorpromazine , imipramine , and maprotiline.
Because its three rings lie in a plane different from th at of the amide group, it
resembles other anticonvulsants as well (27). Carbamazepine is classified as a
neutral lipophilic substance, whi ch enables th e molecul e to pass eas ily through
lipid membranes and facilitates its transport into th e ce ntra l nervou s system.
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Two different metabolic pathways are dis cernible: epoxidatio n of posit ion 10,11
by hepatic monooxygenases, and hydroxylation in one of th e aromatic rings by
hepatic oxygenases. Both metabolites undergo subsequent gluc uronide forma-
tion. The epoxidation pathway is quantitatively the more impor tant one, and
there is speculation that 10, II-epoxycarbamazepine contr ibutes to the drug's
ant iepilept ic (and possible anti-aggressive) activity (28). T here is also evidence
which suggests that carbamazepine induces ce r ta in enzymes, e .g ., cytochrome
P-450 and epoxide hydrase, and may hasten its own degradation . The measured
half-life after a single dose (37 hours) is sign ificantly greater th an the ha lf-life
after repeated doses (28 hours) in multiple trials (28 ).
Animal stud ies initially demonstrated carba mazepine's anticonvulsive
effects and located its site of action in th e limbic region of the brai n. Carbamaze-
pine's anti-epileptic properties were most evident in electricall y-ind uced seizures
in rats and mice, and somewhat less pronounced in ch emicall y ind uced seizures
in these animals. Hypothalamicall y-induced rage in cats was a lso controlled by
ca rbamazepine, suggesting effectiveness in specific types of aggression . In th e
cat epilepsy model, electrical stimulation of var io us limbic st ructures produced
after-discharges recorded in the stimulated structures th emsel ves and interre-
lated areas. The hippocampal aft er-discharge, possibl y invol ved in psychomotor
epilepsy and a particularly useful measure of antico nvulsant efficacy, was
shorte ned by carbamazepine at a dose of 3 mg/kg in ca ts . T he drug had no
effect on the Purkinje cells of th e cerebellar co r te x, suggest ing that the mode of
anticonvulsant action of carbamazepine differs from that of diphenylhydanto in
and diazepam (29). Studies of th e fighting behavior of mi ce suggest that
carbamazepine in high doses has general anti-aggressive an d anxiolytic effects.
Antiparkinsonian and anticholinergic properties also appear o nly at very high
doses. Contrary to clinical reports in humans, trad itional reserpine and amphet-
am ine antagonism trials in animals have not demonstrated antidepressant or
antipsychotic effects. for carbamazepine. To measure car bamazepine's possible
anti-depressant activity, 1,000 mg/kg of th e drug was ad mi nistered to rodents
with reserpine-induced ptosis but produced no antagonistic effect. Similarly, to
test for neuroleptic properties, 300 mg/kg of ca rba mazepine was given to rats
with amphetamine-induced ste reotypy, again without antagonism (29) . These
findings have led investigators to focu s on th e limbic syste m-te mporal lobe area
as the primary site of carbamazepine 's action and to atte mpt to identify possible
neurochemical exp lanat ions for its psychotropic efficacy.
Postulating an association between th e high density of op iate receptors in
th e limbic system and carbamazepine's mech anism of ac tion , Post et al.
measured opioid activity in patients with affective disorders treat ed with
ca rbamazep ine . They reported that th e drug exer te d no significa nt effect on
cerebral spinal fluid (CSF) opioid activity (30), and fou nd no sign ificant associa-
tion between CSF GABA levels and carbamazepine dose or blood level of th e
drug (31). They subsequently examined th e effec ts of ca rbamazepine on
receptors of various major neurotransmitters and oth er substances . Data sug-
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gested that, un like neuroleptics, carbamazepine does not block dopam ine
receptors. It did not produce parkinsonian symptoms, tardive dyskinesia , o r
inhibition or suppression of unit firing dopaminergic neuro ns of the substa ntia
nigra by apomorphine; it did produce minimal elevations of prolactin but did
not diminish cocaine- nor amphetamine-induced hyperactivity. Benzodiazepine
receptor antagonists did not affect ca rbamazepine's anticonvu lsant ac tivi ty in
amygdaloid seizures, suggesting little effect of carbamazepine at th e benzodiaze-
pine receptor as wel l. Carbamazepine failed to inhibit binding at several
recep to r sites, including muscarinic-cholinergic e H-Q N B), dopamine e H-spiro-
peridol) , GABA e H-muscimo l), imipramine , beta-adrenergic e H-DHA), an d
op iate e H-na loxone) receptors. However, di splacement of adenos ine ana logs
was demonstrated, indicating effec ts o n th e adenosin e receptor , and a blockade
of both release and reuptake of norepinephrine , whic h ma y be re lat ed to
carbamazepine 's apparent efficacy in bipolar illn ess (32) . O th er documented
effects of carbamazepine include decreased circ u lat ing T 3 and T 4 , efficacy as a
vasopressin agonist, increased urinary fr ee co r t iso l, and decreased CSF somato-
stat in (32).
Post and his group proposed th at ca rbamazepine , through its an ticonvul-
sant properties, ma y represent a new class of psych otropic agents for the
treatment of affective dysregulation , including aggress io n as a symp to m of a
hyperexcited state or limbic seizure (33). This hypothesis was based on Dalby's
successful use of carbamazepine in patients with te mpora l lobe epilepsy and
mood disorders (34,35), carbamazepine's inhibition of exper imenta lly induced
kindling in the limbic system (particu larly amygda loid se izu res) , and Post an d his
cowor kers' success in treating affecti vely di sordered patients wit h carbamaze-
pine. In Post's model , th ese subcor tica l se izures, wh ich co uld man ifest as
behavioral aberrations such as aggression and psych osis, would no t necessarily
produce EEG abnormal ities; kindling cou ld occur with either environme nta l o r
endogeno us stimuli (36). Heath 's work with deep brain EEG recordings in
epilep tics and schizophrenics also provides so me support for Post 's mode l.
Heath d escribes sei zure-like acti vit y in th e amygdala , hippocampus, an d septa l
region of epilept ics with vio lent psych otic ep isodes wh ich clo se ly resembled the
sp ike and slow-wave patterns obta ined fr om th e same brain regions in nonep i-
leptic aggressive psychotic patients and psychotic sch izo p hren ics (37).
Although the use of carbamazepine in psychiatric patients is increasing as
more data are published, treatment guidelines and side effect profiles have not
ye t been fully agreed upon. Experimental protocol s have suggested ad minis tra-
tion of carbamazepine in doses ranging from 200 mg/d to 2 ,000 mg/ d , wit h
most recommending initial doses of 200-400 mg/d with gra d ual upward
titration to the point of maximum cl inical e fficacy or dose-limiting side effects
(6). Post e t al. report treatment with 1,600-2,000 mg/ d with few side effects
(38). Blood and CSF levels of the drug have been shown to bear no re lat ionship
to clinical response when th e drug is used to treat aggressive psych o tic psych iat-
ric patients, although CSF levels o f carbamazep ine-10 , ll-epoxide correlated
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significantly with clinical response when measured after a month of treatment
(38). Side effects, however, do appear to be related to th e plasm a level in some
patients, becoming more intolerable when the se r um concentration exceeds 9
ug/ml (38). The most commonly reported side effects include diplopia , skin
rash, fatigue , unsteadiness, transient paresthesias in th e extremities, reversible
lupus erythematosis syndrome, nystagmus, drowsiness, na usea, vomiting, and
neutropenia (39). Though decreases in white blood cell counts are usually
clinically insignificant, there have been ca ses of aplastic anemia (40) and
agranulocytosis (4 1) reported with carbamazepine. Other hematologic effects
include thrombocytopenia (42) , reticulocytosis (43), and leukocytosis (44).
Although the incidence of these blood dyscrasias is low, hematologic moni tori ng
should include a complete blood and platelet count prior to th erapy and weekly
comple te blood counts for the first month , followed by monthly whi te b lood ce ll
counts (40). If leukopenia develops, the dose of the drug should be decreased
and the white cell count monitored biweekly. In the event of in fectio n or severe
leukopenia (WBC less than 3,OOO/mm3 o r neutrophil co unt less than 1,500/
mrn "), carbamazepine should be discontinued (4 1).
There are reports of additional side effects and some drug interact ions
involving carbamazepine. Because its ch emical structure is so closely related to
tricyclic antidepressants, carbamazepine may potentiate the action of these
drugs when they are used in combination (39,45). Reiss and O 'D onnell report
two cases of paradoxical carbamazepine-induced mania in chi ld ren with fami ly
histories of affective disorder (46) . Fogelson sugges ts th at ata xia, confusion, and
vomiting can occur when carbamazep ine dosage is increased to o abruptly in
patients previously unexposed to th e drug, as th ey have lower clearance than
those who take it regularly (47 ). At toxic level s, ca rbamazepine is also known to
produce encephalopathy (39) or sch izoph ren ia-like psych osis (48) in susceptible
patients. Kanter et al. described a patient with bipolar disorder wh o was started
on carbamazepine and haloperidol and developed an ac ute organic brain
synd rome with low serum lev els of carbamazepine . The synd rome reso lved with
discontinuation of both medications, and the mania was subsequently controlled
on carbamazepine 200 mg b.i.d. alone. The authors sug ges t th at a central
nervous system interaction between th e two drugs was respo nsib le for the
organic symptoms (49). Lithium carbonate-carbamazepine co mbina tions can
produce signs of neurotoxicity (50,51) , despite therapeutic ser um level s of both
drugs, and th ere is o ne case report of an organic brain synd rome with a lithium
carbonate-carbamazepine-haloperidol combination (52 ). Isoniazid , when given
with carbamazepine, produces delirium (53,54) . There is o ne report of neuro-
toxicity when carbamazepine was combined with metoclopramide (55) . hde
and Post observed significant decreases in se rum sod ium, chori de , and ca lcium
in their patients treated with ca rbamazepine, but th ese cha nges were not
correlated with treatment response , although those patients who im proved on
car bamazepine tended to have greate r depression o f serum sodium level s. T hey
a lso sugge ste d that some " nonspeci fic" sid e effec ts ma y ac tually be symptoms of
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hyponatremia (56), possibly due to water intoxication, whi ch has also been
reported (57 ,58). Finally, carbamazepine administration has somet imes led to
hypothyroidism with and without elevations of th yroid st imu lating hormone
(59 ,32), as well as to hepatitis (60).
Although th e Food and Drug Administration ha s not yet approved the use
of carbamazepine in refractory vio lent psychiatri c patients, th e lite ratu re sug-
gests that this compound, used alone or in combination with conventional
agents, may be beneficial in the treatment of psychoses associat ed with bipolar
affective disorder, schizoaffective disorder, and schizophrenia . T hrough its
anticonvulsant action or another yet unidentified mechanism , carbamazepine
appears to contro l limbic se izu res, which ma y be related to bo th psychosis and
aggression. Familiarity with potential sid e effec ts and drug interactions is
necessary as the use of carbamazepine increases. Finally, additional clinical trials
are necessary to further assess the safety and spectrum of ca rbamazepine's
efficacy.
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